Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda's lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene. Arkuda launched in November 2019 with $44 million from leading life science investors include Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and BioInnovation Capital.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/08/19 | $44,000,000 | Series A |
Atlas Venture Pfizer Venture Investments Tekla Capital Management | undisclosed |
| 02/10/22 | $64,000,000 | Series B |
Atlas Venture Cormorant Asset Management Eli Lilly and Company Mission BioCapital Pfizer Venture Investments Pivotal bioVenture Partners Surveyor Capital Tekla Capital Management | undisclosed |
